Using tumor analytics to improve cancer treatment with immunotherapy and targeted inhibitors
Official title: Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
Funded at Institute for Systems Biology · NIH-11131308 · Data updated 2026-11-12
This study is looking at a new way to treat cancer by using two types of therapies—targeted inhibitors and immunotherapy—in a specific order to see if it works better, especially for people with melanoma and brain metastases, so that patients can have more effective treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $133,520 |
| NIH project number | 3U54CA274509-03S1 |
| Project ID | NIH-11131308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with melanoma or other cancers who are considering immunotherapy or targeted inhibitor treatments.
✕Less likely to help
Patients with cancers that do not respond to immunotherapy or targeted inhibitors may not benefit from this research.
What this research studies
This research focuses on developing a new approach to cancer treatment by combining targeted inhibitors with immunotherapy in a sequential manner rather than simultaneously. By analyzing past clinical data and using advanced therapeutic models, the researchers aim to understand how this sequence can enhance treatment effectiveness, particularly in cases of melanoma and brain metastases. The study will explore various factors such as dosing, timing, and treatment order to optimize patient outcomes. Patients may benefit from more effective treatment strategies that could reduce resistance to therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient survival and quality of life.
How similar studies have gone: Previous research has shown promising results with sequential treatment approaches in cancer therapy, indicating potential for success in this novel approach.
Where this research is happening
-
Institute for Systems Biology
Seattle, United States Active
Researchers
- Principal investigator: Heath, James R. — Institute for Systems Biology
- Study coordinator: Heath, James R.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.